OBJECTIVE -The use of fasting plasma glucose (FPG) level Ն7.0 mmol/l leads to underdiagnosis of type 2 diabetes compared with the oral glucose tolerance test (OGTT). The OGTT is of limited use for population screening. Most of the increase in cardiovascular risk in relation to increasing blood glucose occurs before the threshold at which the diagnosis of type 2 diabetes is made. The aim of this study was to evaluate the use of HbA 1c and FPG as predictors of type 2 diabetes and cardiovascular risk and, accordingly, to develop a rational approach to screening for abnormalities of glucose tolerance.
T he incidence of type 2 diabetes varies from 3.6 to 14.8%, depending on the population being screened (1, 2) and the diagnostic criteria used. Up to 50% of diabetic subjects remain undetected. The oral glucose tolerance test (OGTT) is the gold standard for diagnosing type 2 diabetes. It has limited use for mass screening, due to the need for fasting, the time-consuming nature of the test, and poor reproducibility of the results (3, 4) . The American Diabetes Association (ADA) based diagnosis of diabetes on a fasting plasma glucose (FPG) level of 7.0 mmol/l because this level correlates with a 2-h (post-75 g glucose) level of Ն11.1 mmol/l (5). It was hoped the better reproducibility of FPG and its relative convenience would increase the number of diabetic subjects diagnosed. The ADA also created a new category termed impaired fasting glycemia (IFG) to describe patients with FPG levels of 6.1-6.9 mmol/l (5) to categorize individuals at increased risk for type 2 diabetes and those who may be at increased cardiovascular risk. The World Health Organization (WHO) and subsequently the Australian Diabetes Society similarly adopted an FPG level of 7 mmol/l as the threshold for diagnosing type 2 diabetes (6,7); however, these organizations continue to recommend use of the OGTT, because patients with type 2 diabetes based on an OGTT often have a nondiabetic FPG level (1, 8, 9) .
To improve the detection rate of type 2 diabetes, alternative approaches to screening have been proposed, such as a lower threshold for FPG (8) or the use of HbA 1c (4,10 -12) . Measurement of HbA 1c is used to determine average glycemic control over an 8-to 12-week period, and HbA 1c level has been linked to development of microvascular complications such as neuropathy, nephropathy, and retinopathy (7) . Compared with the OGTT, HbA 1c measurement is quicker, is more convenient, and avoids the need for fasting (3) . Problems with the use of HbA 1c for screening have included variability and poor standardization of assays, biological variability of HbA 1c levels, overlap between subjects with and without diabetes as compared with fasting or 2-h glucose levels (5,14 -17) , and poor sensitivity (12) . When measured using high-performance liquid chromatography (HPLC), however, the test has high precision (interassay coefficient of variation [CV] 1-2%). Furthermore, rapid, on-the-spot results comparable to those obtained with HPLC can be obtained using automated and portable devices (17) .
The current OGTT and FPG thresholds for diagnosis of diabetes are based on their association with microvascular disease, the incidence of which increases sharply above currently defined glycemic thresholds. Macrovascular disease, however, seems to increase gradually in prediabetic states such as impaired glucose tolerance (IGT) and IFG (4, 18) . Given that a major part of the morbidity and mortality from type 2 diabetes arises from macrovascular disease such as ischemic heart disease and not just microvascular disease, any screening test for diabetes would be more meaningful if it could also predict cardiovascular disease. We hypothesized that levels of HbA 1c may increase progressively with increasing plasma glucose levels, even below conventionally defined diabetic thresholds, and are associated with the risk of macrovascular disease.
The aims of this study were 1) to compare the utility of HbA 1c and FPG at different thresholds as screening tests for diagnosing type 2 diabetes, as defined by OGTT criteria; 2) to determine the relationship between HbA 1c and FPG and cardiovascular risk; and 3) to compare HbA 1c measured by HPLC with the result obtained using a portable device (DCA2000; Bayer Diagnostics, Mulgrave, Australia) to assess the potential utility of the latter in screening for type 2 diabetes.
RESEARCH DESIGN AND METHODS

Subjects
Subjects were recruited for this study by community advertisement for people with obesity, family history of diabetes, history of gestational diabetes, or symptoms such as polyuria and polydipsia. All individuals older than 18 years of age without a previous diagnosis of type 2 diabetes were tested if they responded to the advertisement with a request for screening. Pregnant women were excluded from the study. Patients referred by general practitioners and other hospital specialists for an OGTT were offered the opportunity to participate in the study. To determine reproducibility of the tests used, 41 subjects were tested on two occasions (1 week apart). The Ethics Committee of the Royal Adelaide Hospital approved the protocol. Informed consent was obtained from all volunteers.
Study design
Subjects fasted from food and fluid from 11:00 P.M. the previous night and attended the Endocrine Test Unit at the Royal Adelaide Hospital between 8:00 A.M. and 9:00 A.M. Subjects were asked to complete a questionnaire to document the presence of ischemic heart disease, hypertension, and hyperlipidemia and whether there was a family history of type 2 diabetes. Height, weight, and waist circumference were measured. A forearm vein was then cannulated with a 19-g butterfly and 5 ml of venous blood was collected for measurement of glucose and HbA 1c . Thereafter, 75 g of glucose was administered orally and 5 ml of blood was collected at 120 min for measurement of plasma glucose. All patients and their general practitioners were sent a letter informing them of the results, and patients were advised by telephone and by letter to seek follow-up whenever either diabetes or IGT was detected.
Assays
Plasma glucose was measured by the hexokinase method, which has an interassay CV of 1.9% at a glucose level of 4.8 mmol/l. HbA 1c was measured by HPLC using a spherical cation exchange gel, which has an interassay CV of 2% at an HbA 1c level of 6%. HbA 1c results from our laboratory (Institute of Medical and Veterinary Science) were referenced to the National Glycohemoglobin Standardisation Program. HbA 1c was also measured using the DCA2000 (Bayer Diagnostics), a portable device that uses an immunoassay technique with a monoclonal antibody directed against a sequence of the HbA 1c molecule (19) . A result is available within 6 min of testing, with a CV of 2.2%.
Statistical analysis
Results are presented as means Ϯ SD. The receiver operating characteristic (ROC) was used to describe the ability of HbA 1c (HPLC or DCA2000) and FPG to determine the presence or absence of type 2 diabetes as defined by the OGTT. The ROC describes the diagnostic properties of a test by plotting sensitivity as a function of 1-specificity (20) . Sensitivity is the fraction of individuals at or above the HbA 1c cutoff point who have diabetes, whereas specificity is the fraction of individuals with an HbA 1c level below the cutoff point who do not have diabetes. The area under the ROC curve represents the probability that a subject chosen at random from the group with the outcome of interest (type 2 diabetes) had a higher value than a subject without. Wald 2 analysis was used to compare the respective areas under the curve for the different diabetic screening tests. The relationship between HbA 1c as measured by HPLC and using the DCA2000 was determined using linear regression.
Log-binomial regression was used to determine the risk ratios (and 95% CIs) for the presence of ischemic heart disease for each SD increase in HbA 1c , as measured by either HPLC or using the DCA2000 method and the FPG. A risk of 1 was arbitrarily assigned to a cutoff 2 SD below the mean for each of the aforementioned measurements, and risk ratios were then determined for higher levels. The risk ratio was also calculated for each parameter after adjusting for the presence of the other stated risk factors. The reproducibility of measurements of FPG, 2-h glucose, and HbA 1c by each method was calculated for the 41 subjects, who were tested twice, and the intrasubject CV was determined (15) .
RESULTS -A total of 505 subjects aged 19 -88 years (mean age 53.8 years) were studied. There were 294 (58.2%) women and 211 (41.8%) men. Using the Australian Diabetes Society and WHO criteria, the incidence of type 2 diabetes was 10.7% (54 subjects) and the incidence of IGT was 24.4% (123 subjects). Using the ADA criteria, the incidence of type 2 diabetes was 4.0% (20 subjects) and the incidence of IFG was 7.1% (36 subjects).
Subjects were divided according to the presence or absence of diabetes according to OGTT criteria. Nondiabetic subjects had a mean HbA 1c (HPLC) of 5.2% (range 3.5-6.6), a mean HbA 1c (DCA2000) of 5.5% (4 -6.9), and a mean FPG of 5.1 mmol/l (3-6.7). Diabetic subjects had a mean HbA 1c (HPLC) of 6.5% (4.7-12.2), a mean HbA 1c (DCA2000) of 7.0% (5-13.1), and a mean FPG of 7.4 mmol/l (4.7-15.7). There was a good correlation between the HbA 1c values obtained by HPLC and DCA2000 (R 2 ϭ 0.876). The regression data for HbA 1c by DCA2000 versus HPLC reveals a small in-tercept of ϳ0.2 but no change in slope. Accordingly, there is a constant bias of ϳ0.2 but no evidence of relative bias. Based on our ROC curves, our cutoff criteria showed higher values for DCA2000 than HPLC.
Based on an ROC analysis, the areas under the curve (predictive values) of HbA 1 c as measured by HPLC and DCA2000 for detecting type 2 diabetes, compared with OGTT, were 0.893 and 0.911, respectively ( 2 ϭ 0.53, df ϭ 2, P ϭ 0.77) (Fig. 1) .
When measured by HPLC, HbA 1c Ն5.7% predicted type 2 diabetes with a sensitivity of 80.0% and a specificity of 86.3%. HbA 1c levels Ͻ4.7 and Ն6.2% have almost 100% accuracy for predicting the absence and presence of type 2 diabetes, respectively (Table 1) .
When measured by DCA2000, HbA 1c Ն6.2% (sensitivity 72.2%, specificity 94.7%) was the best predictor of diabetes, and HbA 1c levels Ͻ5.0 and Ն6.8% predict the absence or presence of diabetes, respectively, with almost 100% certainty ( Table 1) . Using FPG, the area under the ROC curve was 0.9065. FPG Ն6.0 mmol/l (sensitivity 74.1%, specificity 94.5%) was the best predictor of type 2 diabetes as defined by OGTT. FPG levels Ͻ4.7 and Ն6.4 mmol/l had almost 100% accuracy for detecting the absence or presence of type 2 diabetes.
Cardiovascular risk
The mean Ϯ SD for HbA 1c by HPLC, HbA 1c by DCA2000, and FPG were 5.3 Ϯ 0.74%, 5.6 Ϯ 0.84%, and 5.3 Ϯ 1.2 mmol/l, respectively. The risk ratio (95% CI) for each SD change in HbA 1c by HPLC, HbA 1c by DCA2000, and FPG were 1.3 (1.1-1.5; P ϭ 0.0002), 1.24 (1.1-1.4; P ϭ 0.0038), and 1.26 (1.1-1.4; P ϭ 0.0001), respectively. The relative cardiovascular risks associated with different cutoffs of HbA 1c (HPLC and DCA2000) and FPG are shown in Table 1 .
Neither HbA 1c (HPLC or DCA2000) nor FPG remained independent risk factors for cardiovascular disease after adjustment for age, waist circumference, hypertension, and high cholesterol. After adjustment for these risk factors, the relative risk of ischemic heart disease for HbA 1c by HPLC, HbA 1c by DCA2000, or FPG was 1.1 (0.9 -1.4; P ϭ 0.22), 1.1 (0.8 -1.4; P ϭ 0.64), and 1.2 (0.99 -1.4; P ϭ 0.059). Only age and high cholesterol were independent risk factors for cardiovascular disease. For example, when analyzed with HbA 1c (HPLC) the relative risk of ischemic heart disease for age was 2.0 (1.4 -2.9; P ϭ 0.0002) and for high cholesterol was 2.2 (1.2-3.9; P ϭ 0.01). The ischemic heart disease risk for waist circumference was 1.2 (0.9 -1.6; P ϭ 0.18) and for hypertension was 1.7 (0.8 -3.3; P ϭ 0.14).
Reproducibility
There was a within-subject CV of 2.2% for HbA 1c by HPLC, 2.7% for HbA 1c by DCA2000, 4.9% for FPG, and 16.0% for 120-min plasma glucose after a 75-g oral glucose load.
CONCLUSIONS -These results
show that FPG and HbA 1c (by either method) will diagnose or exclude diabetes with certainty in only a minority (15%) of subjects when the OGTT, with currently defined cutoffs, is used as the gold standard. Although FPG and HbA 1c do not seem to be independent measures of cardiovascular risk, there is a continuous relationship between both of these measures and cardiovascular risk. Moreover, data from the Diabetes Control and Complications Trial (DCCT) (21) and U.K. Prospective Diabetes Study (UK-PDS) (22) demonstrate that there remains a significant risk of microvascular disease with HbA 1c levels well below 8%, and even at an HbA 1c of 6%, there is a 75% If an FPG level Ն7 mmol/l is used, the incidence of type 2 diabetes is underestimated, as compared with the OGTT (1,8,9,24) . Only 4.0% of our subjects were diabetic using FPG based on the ADA criteria, compared with 10.4% using WHO criteria. The detection of type 2 diabetes has been reported by others to halve when ADA as opposed to WHO criteria are applied (1). Wahl et al. (1) showed that at an FPG level of 6.38 mmol/l, the prevalence of diabetes by ADA and 1985 WHO criteria were similar. In the DECODE study, the FPG level that predicted a 2-h value of 11.1 mmol/l was 6.4 mmol/l in men (25). Taken together, the data suggest that an FPG level Ն6.4 mmol/l is the most appropriate level at which to diagnose type 2 diabetes and only 40% (rather than ϳ60%) of individuals with type 2 diabetes would be missed. Our study has also shown that when the FPG level is Ͻ4.7 mmol/l, type 2 diabetes can be confidently excluded; ϳ73% of all subjects had an FPG level between 4.7 and 6.3 mmol/l, and ϳ17% of these individuals had an FPG level of 5.6 -6.3 mmol/l. Of this latter group, 13.6% (12 of 88) were diabetic based on an OGTT.
The relative cardiovascular risk was at least 2 in the group with FPG Ͼ6.3 mmol/l and was 1.7-1.9 in those with an FPG of 5.6 -6.3 mmol/l. Therefore, although an FPG of 5.6 -6.3 mmol/l is associated with a low risk of microvascular disease, there is a relatively high risk of macrovascular disease. Aggressive treatment of cardiovascular risk factors and attention to lifestyle issues such as diet and exercise are indicated. Moreover, we would argue that lifestyle interventions to prevent progression to type 2 diabetes would be most appropriately targeted to this group (26) .
Our data also show that type 2 diabetes is present at an HbA 1c (HPLC) Ն6.2%, and the detection rate is better than when the ADA criteria are used. If an OGTT was performed, however, 57% more of the individuals would have been diagnosed as having type 2 diabetes. An HbA 1c (HPLC) Ͻ4.7% excludes type 2 diabetes. However, ϳ86% of all subjects had an HbA 1c between 4.7 and 6.1%; 21% of these subjects had an HbA 1c of 5.6 -6.1%. Of the latter subjects, 21.5% (23 of 107) were diabetic on the OGTT.
We did not observe an independent relationship between HbA 1c and cardiovascular risk, although such an association has previously been reported in a larger study (20 We have shown that a reduction in the FPG level at which type 2 diabetes is diagnosed will lead to a comparable increase in the detection rate of diabetes. If we combined FPG and HbA 1c , we detected an additional two subjects with diabetes (ϳ4%). We would argue, however, that intervention is more logically based on the risk of complications or associated diseases rather than a comparison with arbitrary cutoffs on the OGTT. In a large meta-analysis, HbA 1c was proposed as a means to identify diabetic subjects requiring pharmacological intervention (3). There is a relationship between HbA 1c and FPG and the risk of both microvascular (4) and macrovascular disease (1, 20) , although the increased risk of macrovascular disease occurs at lower glycemic thresholds.
In contrast to other studies that have evaluated the use of glucose and HbA 1c as screening tests, we studied smaller numbers of subjects prospectively rather than derived data retrospectively but obtained consistent results. Moreover, although we used self-reported data to evaluate cardiovascular risk, our data relating to cardiovascular risk are consistent with the results of other studies demonstrating an association between cardiovascular disease and increasing FPG and HbA 1c , even in the nondiabetic range (18, 20, 29) .
The OGTT is a time-consuming, poorly reproducible, inconvenient, and expensive test that we would argue can largely be avoided in favor of an HbA 1c or FPG, using lower diagnostic thresholds and risk factor assessment to provide the most rational approach to subsequent management. We have proposed an algorithm for how this may occur (Fig. 2) . Using this algorithm, whether with HbA 1c or with FPG, the population is divided into four subsets. The first subset should be considered diabetic because they are at increased risk for cardiovascular and microvascular complications; these subjects should receive standard diabetic assessment (e.g., for retinopathy, neuropathy, and nephropathy) as well as for cardiovascular disease. The second subset is at high cardiovascular risk and at greatest risk for future progression to diabetes. Clinicians should target the cardiovascular risk factors of these subjects and screen for diabetes with HbA 1c or FPG every 12-24 months, depending on previous results. The third subset has a cardiovascular risk above baseline although lower than the first two subsets. In the absence of any other indications, these subjects do not require any specific intervention but could receive general dietary and lifestyle advice as well as appropriate follow-up. The fourth subset is at lowest risk and can be reassured, although it is always appropriate to encourage healthy behaviors. The algorithm in Fig. 2 illustrates this approach using FPG and HbA 1c (HPLC).
Portable devices for measuring HbA 1c are suitable for transport to community settings and, accordingly, provide the potential for mass screening. Fasting is not required and there is no need for further HbA 1c measurement in those subsequently determined to have type 2 diabetes. In situations in which fasting blood glucose can be readily obtained, a cutoff of 6.4 mmol/l results in diagnosis of more diabetic subjects than HbA 1c as well as identification of those at significant risk for cardiovascular disease, in whom maximal intervention, whether pharmacological or nonpharmacological, should be targeted.
